Table 2

Indication for treatment with TCZ

n=93
Joints67 (72.0%)
Skin25 (26.9%)
Lung20 (21.5%)
Myositis2 (2.2%)
Heart1 (1.1%)
Tendinitis2 (2.2%)
Vasculitis1 (1.1%)
Coexisting Castelman-like disease1 (1.1%)
Joints only50 (53.8%)
Joints and skin6 (6.5%)
Joints and lung7 (7.5%)
Joints and myositis1 (1.1%)
Joints, skin and lung3 (3.2%)
Skin only8 (8.6%)
Skin and lung4 (4.3%)
Skin and heart1 (1.1%)
Skin and tendovaginitis2 (2.2%)
Skin, lung and myositis1 (2.2%)
Lung only5 (5.4%)
Vasculitis only1 (1.1%)
Coexisting Castelman-like disease only1 (1.1%)
NA3 (3.2%)
  • NA, not available; TCZ, tocilizumab.